In line with this, although ATM and CHEK2 mutations have been suggested to associate with increased response to DNA-damaging therapy, a recent analysis showed that ATM and CHEK2 mutant pancreatic cancer does not show evidence of HRD by multiple genetic HR classifiers [9]. This evidence concerns the gene ATM and pancreatic neoplasm.